Oncotarget is an ambitious project. It’s a huge journal, which is now released on a weekly basis. It’s grown tremendously over the years, from just eight issues in 2010 to the weekly issues that were put out in 2016. That’s very rapid and impressive growth, and it’s helped the journal’s Impact Factor increase on a yearly basis. More and more people get easy access to important oncology papers and cancer research like Oncotarget. It is one of the most important areas of study for the scientific community, and spreading ideas and information is the key to success.
The two people most responsible for that success are the Editors-in-Chief, Andrei V. Gudkov and Mikhail V. Blagosklonny. Both work at the Roswell Park Cancer Institute, which is located in Buffalo, NY. The main areas of focus that Gudkov woks on include the discovery of new drugs on scimagorjr.com that can be used in cancer treatments, gene discovery, and learning how to use molecular targets when treating cancer. He was trained at Moscow State University and the National Cancer Center.
At the same time, Blagosklonny focuses on cellular and molecular biology, clinical investigation, cell cycle studies, signal transduction, and cellular senescence. He also focuses on anticancer therapeutics, trying to find new strategies to treat cancer using basic science. One of his most recent projects on oncotarget.com helped to connect the use of signal transduction pathways, which were being used in cancer projects, to aging. This is a potentially huge breakthrough that could help slow down age-related diseases and the aging process itself.
With their excellent training and experience, they help to craft the journal so that it really provides the most important information with every single issue that comes out.
However, a project of this magnitude at https://www.dovepress.com/oncotargets-and-therapy-journal can’t be taken on by just two people, and it needs to have a global reach that extends far outside of New York. The founding editorial board includes very talented individuals, such as Frederick Alt, of Harvard Medical School, Zeng Yixin, of the State Key Laboratory in Southern China, and Gerry Melino, of the University of Rome. These are just three examples out of dozens of individuals, but they really help show that global reach and demonstrate just how complete the information provided by Oncotarget truly is.